论文部分内容阅读
目的:探讨长链非编码RNA(lncRNA)91H在结直肠癌(CRC)患者中的表达及其与临床病理特征和预后的关系。方法:抽取我院2010年1月到2012年1月行CRC根治性切除术患者组织标本80例(包括癌组织和癌旁组织),实时荧光定量PCR检测癌组织和癌旁组织中的lncRNA91H表达,设置干扰序列,噻唑蓝(MTT)测定细胞增殖率和流式细胞仪检测细胞凋亡率,COX分析lncRNA91H和预后关系。结果:癌组织lncRNA91H相对表达量为(1.83±0.14),癌旁组织为(0.36±0.07),差异具有统计学意义(P<0.05);lncRNA91H表达在不同TNM分期、肿瘤转移以及浸润深度间差异均具有统计学意义(P<0.05)。多因素COX分析显示,TNM分期、肿瘤转移、浸润深度、lncRNA91H表达是影响CRC预后独立危险因素(P<0.05)。干扰序列作用于lncRNA91H表达后,培养24 h、48 h、96 h时lncRNA91H表达组吸光度(OD)均低于对照组,且随着培养时间的延长,两组OD均显著上升(P<0.05);阴性对照组细胞凋亡率为(5.67±1.23)%,转染lncRNA91H细胞凋亡率为(25.37±0.89)%,差异具有统计学意义(P<0.05)。结论:lncRNA91H可以作为CRC患者预后特异指标,并且与TNM分期、肿瘤转移以及浸润深度间等临床病理特征密切相关。
Objective: To investigate the expression of long chain noncoding RNA (lncRNA) 91H in patients with colorectal cancer (CRC) and its relationship with clinicopathological features and prognosis. Methods: Tissue samples from 80 patients (including cancer tissues and paracancerous tissues) underwent radical resection of CRC from January 2010 to January 2012 in our hospital were collected. The expression of lncRNA91H in cancer tissue and paracancerous tissues was detected by real-time fluorescence quantitative PCR , The interference sequence was set, the cell proliferation rate was measured by MTT and the apoptosis rate was detected by flow cytometry. The relationship between lncRNA91H and prognosis was analyzed by COX. Results: The relative expression of lncRNA91H in cancer tissues was (1.83 ± 0.14) and that in adjacent tissues was (0.36 ± 0.07), the difference was statistically significant (P <0.05). The difference of lncRNA91H expression in TNM stage, tumor metastasis and depth of invasion All were statistically significant (P <0.05). Multivariate COX analysis showed that TNM staging, tumor metastasis, depth of invasion, and lncRNA91H expression were independent risk factors affecting CRC prognosis (P <0.05). The expression of lncRNA91H in lncRNA91H group was lower than that in lncRNA91H group at 24 h, 48 h and 96 h after interference with lncRNA91H expression. OD of both groups increased significantly (P <0.05) (5.67 ± 1.23)% in the negative control group, and (25.37 ± 0.89)% in the lncRNA91H transfected group. The difference was statistically significant (P <0.05). Conclusion: lncRNA91H can be used as a specific marker of CRC prognosis, and is closely related to clinical pathological features such as TNM staging, tumor metastasis and depth of invasion.